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Objective: This research was carried out to investigate the effectiveness, rationality, and safety of lapa-
rotomy management compared with uterine artery embolization (UAE) combined with methotrexate
(MTX) for the treatment of deep implantation cesarean scar pregnancy (CSP II).
Materials and methods: Data from 29 patients seen between June 2008 and February 2012 were retro-
spectively analyzed. The patients were divided into the surgery group and the UAE combined with MTX
group according to the treatment they received. We compared the clinical characteristics and treatment
outcomes between the two groups.
Results: The patients' clinical characteristics did not differ between the surgery group and the UAE
combined with MTX group. However, the mean blood loss was decreased in the surgery group compared
with the UAE combined with MTX group (90 ± 4.5 mL vs. 286 ± 5.2 mL, p < 0.05). No patients required
blood transfusion in the surgery group, whereas two patients in the UAE combined with MTX group
received blood transfusions. The length of time for the serum beta human chorionic gonadotropin (b-
HCG) level to normalize, the time required for the disappearance of the gestational mass, and the
duration of hospital stay were signiﬁcantly less in the surgery group than in the UAE combined with MTX
group (13.7 ± 1.0 days vs. 40.7 ± 1.7 days, 7.1 ± 1.3 days vs. 135.4 ± 6.7 days, and 11.0 ± 1.2 days vs.
41.4 ± 3.2 days, respectively; p < 0.01). Although the treatment success rate did not differ signiﬁcantly
between the two groups, the success rate was 100% for the surgery group and 73% for the UAE combined
with MTX group.
Conclusion: Surgical treatment can remove gestational masses and allow wound repair. Moreover,
laparotomy is available in almost all hospitals. Thus, surgery can be an effective and reasonable treatment
for CSP II.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Cesarean scar pregnancy (CSP) is a rare but very dangerous form
of ectopic pregnancy, characterized by the embryo invading the
myometrium of a previous cesarean scar [1,2]. Patients with CSP
face a high risk of uterine rupture, severe bleeding, hysterectomy,
and fertility loss. The reported incidence of CSP is approximately
1:1800e1:2216 of all cesarean deliveries and accounts for 6% ofs and Gynecology, Afﬁliated
ujin Road, Shanghai 200080,
bstetrics & Gynecology. Publishedectopic pregnancies among women who have previously had a
cesarean delivery [3,4]. In recent years, the cesarean delivery rate
has increased worldwide, which has contributed to a rise in CSP [5].
Vial et al [6] deﬁned two types of CSP. CSP I refers to the im-
plantation of the gestational sac on a previous cesarean scar with
progression in the cervico-isthmus and the uterine cavity. CSP II
refers to a deep implantation of the amniotic sac in a cesarean scar
defect with progression towards the myometrium and the uterine
serosal layer. In CSP II cases, the thickness of the uterine myome-
trium between the gestational sac and the bladder wall is usually
less than 4 mm. Although the former condition may result in a
viable birth, the latter condition has an increased risk of life-
threatening bleeding and uterine rupture during the ﬁrstby Elsevier Taiwan LLC. All rights reserved.
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warranted.
Several treatment options have been reported, including exci-
sion of the gestational sac by laparotomy or laparoscopy, uterine
artery embolization (UAE), medical treatment, and dilation and
curettage. However, there is currently no consensus on the optimal
management for CSP, especially CSP II. In this article, we analyze the
different treatment methods for CSP II patients, including excision
of the gestational sac by laparotomy and by UAE combined with
methotrexate (MTX), and discuss the feasibility and rationality of
different management options.Materials and methods
Patients
Our study was approved by the ethics committee of Shanghai
Jiaotong University. Data from 29 patients diagnosed with CSP II in
Shanghai Jiaotong University Afﬁliated Shanghai First People's
Hospital between June 2008 and February 2012 were retrospec-
tively evaluated. All patients had a history of previous cesarean
delivery. The diagnosis of CSP II was made with a positive preg-
nancy test and transvaginal sonography. According to the literature
[2,7,8], the ultrasound diagnostic criteria are the following: no ev-
idence of gestation found in the uterine cavity or endocervical ca-
nal; the gestational sac is implanted in the anterior isthmic wall of
the uterus; a thin or absent myometrial layer is present between
the gestational sac and the bladder; and color power Doppler im-
ages show a hypervascular signal in the cesarean scar area.Treatment methods
The patients were divided into two groups according to the
management method used: 14 patients underwent surgery (sur-
gery group) and 15 patients underwent UAE combined with MTX
(UAE combined withMTX group). In the surgery group, the patients
underwent excision of the gestational mass and scar repair by
laparotomy.
UAE was performed by an experienced radiologist. After the left
or right femoral artery was successfully punctured, a 5F Roberts
uterine catheter was superselectively inserted into the bilateral
uterine arteries, and 100 mg of MTX was infused bilaterally via the
uterine catheter. Once the blood ﬂow slowed, gelatin sponge par-
ticles were used to block the uterine arteries until blood ﬂow was
occluded. Angiography was performed to conﬁrm embolization.
The serum beta human chorionic gonadotropin (b-HCG) level was
monitored weekly following UAE. If the b-HCG level dropped by
less than 50%, the patients received a 1 mg/kg dose of MTX
intramuscularly.Table 1
Clinical characteristics of patients with CSP II.
Characteristics Surgery gr
Age (y) 31.1 ± 1.8
Number of previous cesarean deliveries 1.2 ± 0.1
Time since last cesarean delivery (y) 2.4 ± 0.3
Gestational age (d) 47.1 ± 3.8
Diameter of gestational sac (mm) 30.5 ± 1.2
Thickness of anterior lower uterine segment myometrium (mm) 2.5 ± 0.6
Serum b-HCG level (mIU/mL) 8776 ± 23
Data are presented as mean ± standard deviation.
b-HCG ¼ beta human chorionic gonadotropin; CSP ¼ cesarean scar pregnancy; MTX ¼ mEvaluation of results
Serum b-HCGmeasurements and color transvaginal sonography
examinations were performed weekly. The clearance time of serum
b-HCG, the clearance time of the gestational mass as veriﬁed by
transvaginal sonography, amount of hemorrhage, duration of the
hospital stay, failure rate of the treatment, side effects, and com-
plications were recorded. An outcome of failure was deﬁned as
massive hemorrhage (>500 mL), continuous or plateau serum b-
HCG levels, or the need for a hysterectomy.
Statistical analysis
SPSS 11.0 software was used for the statistical analysis, and the
data were expressed as the means ± standard deviation. The
nonparametric ManneWhitney test was used to compare the blood
loss, time for serum b-HCG to return to normal, time for the
gestational mass to resolve, and duration of hospital stay. Fisher's
exact test was used to compare the success rates. All p values <0.05
were considered signiﬁcant.
Results
Clinical characteristics
All of the patients presented with amenorrhea. In addition, 25
patients reported a small amount of vaginal bleeding, 21 com-
plained of low abdominal pain or low back pain, and ﬁve presented
with isolated amenorrhea. The physical examination showed that
the uterus was of nongravid size or the size of a 6-week gestation
pregnancy in all patients. The serum b-HCG level was increased in
all patients. All of the patients met the diagnostic criteria for CSP II.
Themean age, mean parity, number of previous cesarean deliveries,
duration since last cesarean delivery, gestational sac diameter,
thickness of the anterior lower uterine segment myometrium, and
gestational age are displayed in Table 1.
Comparison of blood loss and success rate between the surgery
group and the UAE combined with MTX group
Fourteen patients underwent excision of the gestational mass
and wound repair by laparotomy. In all cases, the fallopian tubes
and ovaries appeared normal; however, we observed a blue-tinted
gestational sac located in the previous cesarean scar and protruding
into the uterine serosal surface. The anterior uterus myometrial
wall was very thin or absent. No blood was found in the abdominal
cavities of the patients, and the mean blood loss for patients who
underwent surgery was 90 ± 4.5 mL (range 40e150 mL). Fifteen
patients were treated with UAE combined with MTX, and all
received MTX intramuscularly (weekly for 2e3 weeks) because the
serum b-HCG level failed to decrease. Severe vaginal bleedingoup (n ¼ 14) UAE combined with MTX group (n ¼ 15) p
31.7 ± 1.7 0.82
1.1 ± 0.1 0.74
1.9 ± 0.2 0.61
43.7 ± 1.4 0.34
31.3 ± 1.1 0.52
2.7 ± 0.4 0.23
5 8302 ± 367 0.35
ethotrexate; UAE ¼ uterine artery embolization.
Table 2
Comparison of blood loss and success rate in the surgery and UAE groups.
Surgery group (n ¼ 14) UAE combined with MTX group (n ¼ 15) p
Blood loss (mL), mean ± SD 90 ± 4.5 286 ± 5.2 mL <0.05
Success rate (%) 14/14 (100%) 11/15 (73%) >0.05
MTX ¼ methotrexate; SD ¼ standard deviation; UAE ¼ uterine artery embolization.
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after UAE combined with MTX. These four patients underwent
emergency laparotomy for excision of the gestational mass. Two of
those patients received a blood transfusion because of excessive
blood loss. The patients managed with UAE combined with MTX
had a mean blood loss of 286 ± 5.2 mL (range 130e1000 mL). No
patient in either group underwent a hysterectomy. As shown in
Table 2, the blood loss in the surgery groupwas less than in the UAE
combined with MTX group (p < 0.05). The success rate was 100% in
the surgery group and 73% in the UAE group, although this differ-
ence was not signiﬁcant.
Comparison of clinical characteristics after the treatment and
duration of hospital stay
The serum b-HCG level returned to normal within 13.7 ± 1.0
days postoperatively in patients who underwent surgery (range
10e18 days). The mean period for the serum b-HCG level to return
to normal was 40.7 ± 1.7 days (range 30e55 days) in patients
treated with UAE combined with MTX (p < 0.05; Table 3).
Patients in the surgery group were examined by transvaginal
ultrasound 7 days (mean 7.1 ± 1.3 days) postoperatively, with no
intrauterine mass identiﬁed. Patients in the UAE combined with
MTX group were monitored by weekly transvaginal ultrasound
after the treatment until the serum b-HCG was negative, and the
intrauterine masses in these patients disappeared from 90 to 180
days after the procedure (mean 135.4 ± 6.7 days; Table 3).
As shown in Table 3, the mean duration of hospital stay was
9.0 ± 1.2 days (range 7e15 days) in patients who underwent sur-
gery and 41.4 ± 3.2 days (range 34e64 days) in patients treated
with UAE combined with MTX (p < 0.01).
Comparison of complications between the two groups
Patients who underwent surgery did not suffer any complica-
tions. Vaginal bleeding stopped 7e10 days postoperatively. The
most common complications in patients treated with UAE com-
binedwithMTX included lower abdominal pain (8/15), fever (5/15),
and nausea and vomiting (4/17). All patients in the UAE combined
with MTX group had more than 30 days of vaginal bleeding, and
three patients presented with infection and were treated with
antibiotics.
Discussion
CSP is a rare but life-threatening type of ectopic pregnancy and
should be treated as quickly as possible after its diagnosis.Table 3
Comparison of characteristics after the treatment and duration of hospital stay.
Surgery group (
The time for serum b-HCG level to return to normal (d) 13.7 ± 1.0
The time required for gestational mass disappearance (d) 7.1 ± 1.3
Duration of hospital stay (d) 11.0 ± 1.2
b-HCG ¼ beta human chorionic gonadotropin; MTX ¼ methotrexate; UAE ¼ uterine arteGenerally, termination of the pregnancy in the ﬁrst trimester is
recommended. Treatment options for CSP include medical treat-
ment, surgery, UAE, or a combination of these methods; however,
the optimal treatment is not yet known. Management should be
personalized to the patient with consideration for the CSP type,
gestational age, future fertility, and gestational viability [9].
CSP II presents a greater treatment challenge than CSP I. UAE
was initially adopted as a treatment for gynecologic and obstetric
hemorrhage conditions, such as postpartum hemorrhage, uterine
myoma, and cervical pregnancy. Recently, UAE has gained wide
acceptance as a treatment for CSP [10,11], and MTX has been re-
ported as an alternative treatment for CSP but with a high failure
rate. The administration of intravascular MTX prior to occlusion
facilitates a high MTX concentration in the CSP mass with less
toxicity and fewer adverse effects compared with systemic MTX
administration [12]. UAE combined with MTX not only blocks the
blood ﬂow to the CSP but also has a direct embryocidic effect. This
combination has been an effective method for the treatment of
CSP [13]. Zhang et al [14] reported that 11 patients with CSP un-
derwent UAE combined with MTX followed by uterine curettage,
resulting in the successful treatment of 10 patients. However,
uncontrolled hemorrhage occurred during curettage in one pa-
tient, and open surgical excision of the low segment of the uterus
was performed. The authors suggested that UAE combined with
MTX followed by uterine curettage might be an effective and safe
method to treat CSP. Takeda et al [15] described UAE as an initial
conservative method used for ﬁve CSP cases with total or subtotal
placental invasion to the anterior uterine wall. Additional MTX,
hysteroscopic resection, or MTX plus hysteroscopic removal were
administered in four cases, and spontaneous expulsion of gesta-
tional products occurred in one case. The authors posited that CSP
with deep placental invasion to the anterior uterine wall is difﬁ-
cult to manage conservatively, and that additional medical and/or
surgical measures should be individually used. Our study
demonstrated that all CSP II patients treated with UAE combined
with MTX required systemic MTX application, with four of 15
patients suffering from severe bleeding. Our ﬁndings suggest that
UAE combined with MTX is not a good option for the treatment of
CSP II.
Laparotomy is available in all hospitals and is effective for the
removal of the gestational mass and scar repair. If uterine scar
dehiscence accompanies cesarean scar implantation, potentially
affecting future pregnancies, only surgical resection offers the op-
portunity to remove the pregnancy and simultaneously repair the
defect, restoring the potential for successful subsequent pregnan-
cies [13,16]. Resection of the old scar and the new closure can
minimize the risk of recurrence [6].n ¼ 14) UAE combined with MTX group (n ¼ 15) p
40.7 ± 1.7 <0.01
135.4 ± 6.7 <0.01
41.4 ± 3.2 <0.01
ry embolization.
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the treatment of CSP. We found that the mean blood loss, duration
of hospital stay, and time for serum b-HCG level to return to normal
were less in the surgery group than in the UAE combined with MTX
group. Although there was no signiﬁcant difference in the success
rates between the two groups, the surgery group success rate was
100%, whereas the UAE group success rate was 73%. Our study
showed that if UAE combinedwithMTXwas performed as an initial
treatment for CSP patients with deep invasion to the uterine wall,
all the patients would require further treatment, which could in-
crease the cost of treatment, duration of hospital stay, and risk of
complications.
For patients with stable hemodynamics, the treatment aims to
excise the gestational mass and preserve future fertility. Simulta-
neous resection of the scar with the gestational mass and wound
repair is a feasible method to treat CSP. This method can repair the
wound in addition to terminating the pregnancy, decreasing the
risk of recurrence, and preserving future fertility. However, some
researchers believe that laparotomy can increase postoperative
adhesions and affect fertility [6].
Laparoscopy is a minimally invasive procedure for CSP and can
remove gestational tissue and allow for wound repair. The ﬁrst CSP
case successfully treated by laparoscopy was reported in 1999 [17],
with several other successful cases reported since then. Laparos-
copy can conﬁrm the diagnosis, remove the gestational products,
and repair the uterine defect. Some researchers have suggested that
laparoscopy may be a reasonable alternative to laparotomy for an
unruptured CSP [18]. Recently, Wang et al [19] reported that 11
patients with CSP II were successfully managed by laparoscopy or
by laparoscopy combined with a transvaginal approach. In their
study, the average operative time was 85.5 ± 17.5 minutes, and the
mean blood loss was 250.0 ± 221.4 mL. The serum b-HCG level
returned to <100 mIU/mL within 16.4 ± 5.3 days postoperatively.
Thus, in hospitals that offer laparoscopy, laparoscopic CS resection
with wound repair is a safe and effective treatment for CSP II,
especially after the failure of medical treatment.
In conclusion, our study suggests that resection of the gesta-
tional mass and wound repair is a safe and effective treatment for
CSP II. Our ﬁndings are limited by our small retrospective study
design. Further randomized cohort studies are warranted to eluci-
date the optimal treatment for CSP II.
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